Imaxio and VitamFero announce the conclusion of an R&D partnership agreement. According to the terms of the agreement, the two firms will evaluate the combination of IMX313, Imaxio’s pro-immunogenic technology, and VitamFero’s live attenuated parasites, for vaccines development.